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By virtue of its direct contact with the environment, the lung is constantly challenged by infectious and non-infec-
tious stimuli that necessitate a robust yet highly controlled host response coordinated by the innate and adaptive
arms of the immune system. Mammalian Toll-like receptors (TLRs) function as crucial sentinels of microbial and
non-infectious antigens throughout the respiratory tract and mediate host innate immunity. Selective induction of
inflammatory responses to harmful environmental exposures and tolerance to innocuous antigens are required to
maintain tissue homeostasis and integrity. Conversely, dysregulated innate immune responses manifest as sustained
and self-perpetuating tissue damage rather than controlled tissue repair. In this article we review aspects of Toll-like
receptor function that are relevant to the development of acute lung injury and chronic obstructive lung diseases
as well as resistance to frequently associated microbial infections.
Introduction
As an essential interface between the environment and
the internal milieu, the lungs are continuously exposed to
dust, pollen, chemicals, and microbial pathogens. Pneu-
monia and related patterns of lower respiratory tract
infection are a frequent consequence of this interaction
and account for a significant proportion of human mor-
bidity and mortality throughout the world [1,2]. To con-
tain potential environmental threats, the lungs are
equipped with complex and multifaceted host defences.
During tidal ventilation, the complex geometry of the
nasal passages and branching pattern of the central air-
ways impede the penetration of relatively large or heavy
infectious particles while tight intercellular junctions
ensure the structural integrity of the lung epithelium.
This barrier is enhanced by airway goblet cells that
secrete mucus and ciliated epithelial cells that constantly
transport this viscous layer towards the bronchi and away
from the alveoli to facilitate expulsion of trapped parti-
cles [3]. A variety of soluble host defence mediators such
as secretory IgA, antimicrobial peptides, surfactant pro-
teins, lactoferrin, and lysozyme also bolster the mucosal
defences of the lower respiratory tract. Finally, resident
alveolar macrophages (AMs) and airway mucosal dendri-
tic cells (DCs) provide constant surveillance for poten-
tially pathogenic factors while inhibiting T cell responses
to myriad non-pathogenic antigens [4]. These normal
host defences ensure that most encounters between the
respiratory tract and pathogens are inconsequential;
nevertheless, in response to prolonged, intense, or highly
virulent microbial exposure, an inflammatory response or
productive infection is likely to occur. To rapidly initiate
an acute inflammatory response in these circumstances,
the lung epithelium, myeloid cells, and associated lym-
phoid tissue are all equipped with a series of highly con-
served pattern recognition receptor (PRRs) including
Toll-like receptors (TLRs), NOD-like receptors (NLRs),
and RIG-I like receptors (RLRs). PRR activation leads to
the release of cytokines and chemokines that attract leu-
kocytes to the site of infection and trigger the maturation
and trafficking of antigen presenting cells for induction
of adaptive immunity (figure 1). The purpose of this arti-
cle is to review the role of TLRs in the pathogenesis or
consequences of acute lung injury (ALI) and chronic
inflammatory lung diseases including asthma, chronic
obstructive pulmonary disease (COPD), and cystic fibro-
sis (CF).
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Microbial ligands
Constant interactions between the respiratory tract and
t h ee n v i r o n m e n tp o s eam a j o rc h a l l e n g et oh o s ti m m u -
nity and necessitate robust surveillance mechanisms to
distinguish innocuous from pathogenic exposures. One
strategy that is used by TLRs for selective induction of a
host response is recognition of unique microbial struc-
tures termed pathogen-associated molecular patterns
(PAMPs) [5-8]. Eleven functional TLR genes that play
diverse roles in host defense, inflammation, autoimmu-
nity, and neoplasia have been discovered in mouse and
man (mouse TLR10 is a pseudogene and human TLR11
encodes a truncated protein) [5]. Prototypic examples of
PAMPs include lipopolysaccharide (LPS), a outer mem-
brane component of Gram-negative bacteria that stimu-
lates TLR4 [8,9], bacterial lipoproteins that stimulate
TLR2 in conjunction with either TLR1 or TLR6 [10],
and flagellin, the protein monomer of bacterial flagella
that activates TLR5 [11]. Nucleic acids are recognized
by endosomal TLRs; double-stranded DNA with
unmethylated CpG motifs activates TLR9 in a host spe-
cies-specific manner while TLR3 and TLR7/8 are acti-
vated by dsRNA including synthetic poly (I:C) [12] and
ssRNA, respectively [13,14].
Host-derived ligands
Following the discovery that TLRs discriminate self from
non-self through their intracellular localization or recog-
nition of distinct ligand signatures, evidence was gath-
ered in support of the hypothesis that endogenous host
molecules termed danger associated molecular patterns
(DAMPs) also stimulate TLRs. The first suggestion of
this process came from studies of heat shock protein
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Figure 1 Innate and adaptive immunity in acute and chronic lung inflammation. A variety of host and environmental factors contribute to
the development of acute and chronic lung inflammation. Recognition of pathogen associated molecular patterns (PAMPs) or endogenous
damage associated molecular patterns (DAMPs) by host pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), elicits innate
immune responses that subsequently instruct adaptive immunity. Recovery from the inciting stimulus depends on robust yet tightly regulated
innate and adaptive immune responses. Deficient innate immune signaling leads to excess pathogen burden while an exaggerated response
can cause severe tissue injury and death of the host.
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ligands including the extra domain A of fibronectin and
hyaluronic acid were also shown to activate TLRs
[16,17]. Recognition of endogenous ligands by TLRs
may also contribute to the onset and initiation of auto-
immune responses. For example, the high mobility
group box protein 1 (HMGB1) protein that normally
resides in the cell nucleus can activate TLR2 and induce
hallmarks of lupus-like disease when released from
apoptotic cells as a complex with nucleosomes [18].
TLR signaling
The activation of TLRs results in acute inflammation and
controls the adaptive immune response at various levels.
Partially overlapping intracellular signaling pathways
downstream of each TLR activate specific transcription
factors that regulate the expression of genes responsible
for inflammatory and immune responses. Four adaptors
that harbour a Toll-Interleukin-1 Receptor (TIR) domain,
including MyD88, TIRAP (MAL), TRIF (TICAM1), and
TRAM, connect the TLRs to the cytoplasmic signaling
machinery [5]. MyD88 was initially identified as part of
the interleukin (IL) -1R and IL-18R signalling pathways
and was subsequently implicated in signalling by almost
all TLRs to trigger NF-B, Interferon Regulatory Factor
(IRF) 5, and Mitogen Activated Protein (MAP) kinase
activation. A notable exception is TLR3 that mediates the
activation of IRFs exclusively through the adaptor mole-
cule TRIF [19]. The function of TIRAP is to recruit
MyD88 to TLR2 and TLR4 at the plasma membrane,
while TRAM recruits TRIF to TLR4 for activation of
IRF3. A fifth adaptor protein, SARM, negatively regulates
TRIF-dependent signaling [20,21]. Activation of different
intracellular signaling mechanisms through TLRs results
in the induction of distinct gene programs and cytokine
expression patterns that control the recruitment of
downstream molecules and regulate the identity,
strength, and kinetics of gene and protein expression.
More detailed reviews of the TLR signalling pathways
have been published elsewhere [22-24].
The potent stimulatory responses mediated by TLR
signaling must be tightly regulated at numerous levels in
order to prevent the deleterious consequences of exces-
sive innate immune activation [25]. For example, soluble
forms of TLR4 and TLR2 may function as decoy recep-
tors to terminate ligand interactions with membrane
bound TLRs [26]. Furthermore, IRAK-M has 30-40%
homology to the other IRAK-family members and stabi-
lizes the TLR-MyD88-IRAK4 complex, leading to a
unique negative regulatory influence on TLR signaling
[27,28]. TLR signaling is also inhibited by transmem-
brane receptors like ST2, SIGIRR, and TRAILR while
proteins such as Tollip [29], SARM [21], an inducible
splice variant of MyD88 (MyD88s) [30], and the
suppressor of cytokine sign a l i n g1( S O C S 1 )[ 3 1 ]a r e
responsible for modulation of intracellular TLR
signaling.
In addition to TLRs, a variety of other PRRs including
the cytoplasmic NLRs and RLRs play important roles in
the induction of lung inflammation. For example, the cyto-
plasmic NALP3 protein, a member of the NLR family that
triggers assembly of the caspase-1 inflammasome and pro-
duction of mature IL-1b, was recently implicated in the
development of asbestos or silica-induced pulmonary
fibrosis [32]. RLRs on immune and non-immune cells
recognize viral RNA species and induce host responses
through the adaptor IPS-1. Several putative cytosolic
detectors of double-stranded DNA including DAI (ZBP1-
DLM1) and AIM2 have also been identified; however their
roles in lung diseases have not been established. A detailed
discussion of these important non-TLR innate immune
receptors is beyond the scope of this article; however,
interested readers may consult other sources [33].
Expression and function of TLRs in lung cells or
tissue
TLRs are widely expressed on both resident lung cells as
well as infiltrating cells of myeloid and lymphoid origin.
Primary bronchial epithelial cells express mRNA for
TLR1-10 and secrete the chemokine CXCL8 (IL-8) in
response to various TLR ligands [34]. Human AMs have
been shown to express low levels of TLR3, TLR5, and
TLR9 and higher levels of TLR1, TLR2, TLR4, TLR7, and
TLR8 [35,36]. Lung endothelial cells express TLR4 that is
crucial for neutrophil recruitment and capillary seques-
tration following systemic LPS administration [37]. Neu-
trophils that localize to the lung vasculature in response
to LPS express TLR1, TLR2, TLR4, TLR5, and TLR9
[38]. Several DC subsets have been identified in the
mouse and human lung and can be distinguished accord-
ing to their surface marker expression and anatomical
location [39,40]. Lung DCs act as sentinels that are acti-
vated by TLR ligation in order to bridge innate and adap-
tive immunity. Lung plasmacytoid DCs (pDCs) express
uniquely high levels of TLR7 and TLR9 that suppress the
allergic response and regulatory lung DCs give rise to
regulatory T cells [41]. Notably, in some cases the level
of TLR transcription in cells does not correlate with
functional responses [35,36]. For example, following sti-
mulation with LPS or mycobacterial DNA, human AMs
produced higher levels of the inflammatory cytokine
TNF-a while interstitial macrophages produced higher
levels of the immunoregulatory cytokines IL-6 and IL-10
despite similar levels of TLR mRNA [35]. Finally, lung
tissue cells may also be activated through cooperative
interactions with TLR responsive lymphoid cells, as
exemplified by airway smooth muscle cell activation via
IL-1b release from LPS-stimulated monocytes [42]. Thus,
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cell intrinsic mechanisms as well as cooperative actions
of both resident and recruited cell populations.
Acute Lung Injury (ALI)/Acute Respiratory Distress
Syndrome (ARDS)
ALI or ARDS is a life-threatening condition that is char-
acterized by increased inflammatory cytokine expression
and cell infiltration into the lungs, non-cardiogenic pul-
monary edema, and diffuse alveolar damage that cul-
minates in respiratory failure [43,44]. ALI can be a
consequence of bacterial or viral infection or may be trig-
gered by non-infectious insults including environmental
toxin exposure (ozone, heavy metals), trauma, or hyper-
oxia. TLRs mediate ALI through recognition of microbial
PAMPs or through detection of endogenous DAMPs
(hsp, hyaluronan, fibrinogen, HMGB1 [16,45-50], both of
which trigger inflammation [51-57]. Depending on the
specific nature and intensity of the inciting stimulus, this
response can be beneficial (maintenance of tissue integ-
rity and repair) or detrimental (increased fibrosis and
fluid in the lungs) for host recovery (figure 1) [43,57,58].
In this review we will focus on the contribution of TLR
signaling to a subset of clinically relevant causes of ALI.
Non-infectious causes of ALI/ARDS
Hemorrhagic shock (HS) is common in trauma patients
and can prime the host immune response to elicit
excessive inflammation, neutrophil influx and tissue
injury in response to a secondary stimulus, causing ALI
through the so-called ‘two-hit hypothesis’ [59-61]. Well
characterized mouse models of HS-induced ALI using
LPS as the secondary stimulus have determined that
cross talk between TLR2 and TLR4 elicits heightened
inflammatory mediator expression, such as CXCL1,
leading to increased neutrophil influx and pulmonary
edema [55,60,62-64]. Early inflammation in HS-induced
ALI is dependent on upregulation of TLR4 by LPS,
while later inflammation is mediated by heightened
TLR2 expression on AMs and endothelial cells [64].
Deletion of either TLR2 or TLR4 in mice conferred pro-
tection from ALI and confirmed the presence of cross
talk between these two receptors [63,65].
Hyperoxia (high concentrations of inspired oxygen) is
a common therapy in critically ill patients; however, this
treatment can also cause severe ALI by upregulating the
production of reactive oxygen species [44,66-69]. TLR4
protects the host from hyperoxia-induced ALI by main-
taining lung integrity and inducing the expression of
protective anti-apoptotic factors such as Bcl2 and Phos-
pho-Akt [70,71]. TLR4 or TLR2/TLR4 double knockout
mice exposed to hyperoxia have significantly greater
lung inflammation and permeability and are more sus-
ceptible to lethal ALI compared to wild type mice
[71,72]. Conversely, TLR3-deficient mice are protected
from ALI due to decreased neutrophil recruitment,
induction of pro-apoptotic factors, and increased surfac-
tant protein expression that clears injury-induced cellu-
lar debris [73-75].
Bleomycin is a potent anticancer agent that ultimately
leads to cell death through generation of oxygen radicals
and DNA breaks [76]. Bleomycin toxicity is usually asso-
ciated with diffuse pulmonary fibrosis but may also
cause ALI by triggering the degradation of high molecu-
lar weight hyaluronan (HA) in the extracellular matrix
[77-79]. In contrast to intact HA that mediates homeos-
tasis, accumulation of low molecular weight HA frag-
ments is detrimental because it induces relentless
pulmonary inflammation in AMs [72,78]. Loss of TLR2
and TLR4 or the adaptor molecule MyD88 leads to
increased tissue injury, epithelial cell apoptosis and
decreased survival following bleomycin exposure as well
as decreased chemokine expression and defective neu-
trophil recruitment to the lungs [72]. Further mechanis-
tic studies showed that TLR2 and TLR4 not only trigger
basal NF-B activation at the lung epithelium through
interactions with intact HA in order to maintain cell
integrity and decrease lung injury, but also mediate
macrophage inflammatory responses to HA fragments
following chemically induced tissue injury [72,80].
Infectious causes of ALI/ARDS
Pneumonia is the most common cause of ALI or ARDS
[81]. During the past decade, novel and highly virulent
respiratory viruses, such as the Severe Acute Respiratory
Syndrome Coronavirus (SARS CoV), have emerged as
important causes of excessive lung damage in infected
humans [82]. The 2003 global SARS epidemic had a
50% mortality rate with 16% of all infected individuals
developing ALI [83,84]. The lung pathology in these
patients mirrored ALI caused by other factors, consist-
ing primarily of diffuse alveolar damage caused by virus-
alveolar cell interaction [85]. The contribution of TLRs
to SARS pathogenesis is not well understood [86]; how-
ever, using different mouse models of related CoV infec-
tion, a protective role for TLR4 [87] and MyD88 [88]
has been suggested while TLR7 may be important for
viral clearance through production of type I IFN [89].
Highly pathogenic strains of influenza virus are another
important cause of ALI/ARDS in humans. Compared to
seasonal influenza strains that bind cells of the upper
respiratory tract, highly pathogenic H5N1 influenza virus
infects alveolar type II cells, macrophages, and non-
ciliated cuboidal epithelium of the terminal bronchi lead-
ing to a lower respiratory tract infection and ALI/ARDS
[90,91]. Modeling of H5N1 infection in mice reproduced
the pattern of damage seen in humans including
increased neutrophilia, alveolar and interstitial edema,
Lafferty et al. Journal of Inflammation 2010, 7:57
http://www.journal-inflammation.com/content/7/1/57
Page 4 of 14lung hemorrhage, and elevated TNF-a and IL-6 expres-
sion in the airway lining fluid [92,93]. Mice that survived
beyond the acute phase of infection had large regions of
lung interstitial and intra-alveolar fibrosis and ALI [93].
The role of TLRs has been intensively studied in
influenza infection. TLR7 expression on pDCs plays a
cell-specific role against influenza through MyD88-
dependent IFN-a induction [13,94]. Despite the impor-
tance of TLR7/MyD88 signaling, MyD88-deficient mice
c a ns t i l lp r o d u c et y p eII F N ,control viral replication,
and recover from the infection [95]. An increased lung
viral load was seen only when MyD88 and IPS-1 (the
adaptor molecule for the cytosolic RIG-I pathway) were
both absent, suggesting that these pathways can compen-
sate for one another during influenza infection [95].
Though not essential for survival, MyD88 does play a dis-
tinct role in the adaptive immune response to influenza
through regulation of B-cell isotype switching [95,96].
T h er o l eo fT L R 3i nt h ei m m u n er e s p o n s et oi n f l u -
enza has been debated in the literature. Although several
studies have shown that dsRNA is not produced during
influenza replication [97,98], very low and potentially
undetectable levels of this viral intermediate could still
elicit a substantial immune response through TLR3
[99,100]. The finding that TLR3 is upregulated in
human bronchial and alveolar epithelial cells during
influenza infection suggests that it may play an impor-
tant role in immune signaling [101]. Deletion of TLR3
leads to downregulation of inflammatory cytokine and
chemokine production and an elevated viral load during
the late phase of influenza infection. Surprisingly, TLR3
mutant mice have an increased survival rate compared
to wild type mice suggesting that TLR3 signaling is det-
rimental to the host, despite its role in reducing viral
replication [102,103]. In addition to the TLRs, RIG-I,
NLRP3, and NOD2 have also been implicated in the
immune response to influenza [104-108]; however, the
relative contribution of these PRRs to influenza-specific
host defense requires additional study.
TLRs in chronic pulmonary diseases
Cystic Fibrosis (CF)
CF is an autosomal recessive disorder caused by muta-
tions in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene [109]. The airways of CF patients
are characterized by chronic bacterial colonization and
associated neutrophilic inflammation. P. aeruginosa
infection is the major cause of morbidity and mortality
among CF-affected individuals, producing acute pneumo-
nia or chronic lung disease with periodic acute exacerba-
tions [3,110,111]. A predisposition to chronic and
progressive P. aeruginosa infection occurs despite the
finding that both CF and non-CF lung epithelial cells
express functional TLRs that can mediate inflammatory
responses to microbes. For example, in one study com-
paring human CFTE29o (trachea; homozygous for the
delta F508 CFTR mutation) and 16HBE14o (bronchial
non-CF) cells, comparable mRNA and surface protein
expression of TLR1-5 and TLR9 was observed [112].
TLR6 mRNA, but not protein, expression was observed
in both cell lines; however, for unclear reasons only the
CF line responded to TLR2/TLR6 agonist MALP-2 [112].
Despite this similar TLR expression pattern, a more
recent study showed increased inflammatory responses
following stimulation with clinical Pseudomonas isolates
in a CF airway epithelial cell line (IB3-1) compared to a
“CF-corrected” line stably expressing wild type CFTR
[113]. A detailed analysis showed that these responses
were dependent on bacterial flagellin and TLR5 expres-
sion. Peripheral blood mononuclear cells from CF
patients also responded more vigorously to stimulation
with P. aeruginosa and TLR ligands compared to healthy
controls and expressed higher levels of TLR5 mRNA,
suggesting that CFTR mutations modulate the host
inflammatory response through undetermined mechan-
isms [113]. In another study, a selective increase in TLR5
expression was found on airway, but not circulating, neu-
trophils from CF patients compared to patients with
bronchiectasis and healthy control subjects [38]. The
functional relevance of neutrophil TLR5 expression was
reflected by its correlation with lung function values in P.
aeruginosa-infected CF patients. Neutrophils also had
increased flagellin dependent IL-8 secretion, phagocyto-
sis, and respiratory burst activity that were attributed to
chronic infection rather than as a primary consequence
of mutant CFTR [38]. TLR5-deficient mice showed
impaired bacterial clearance, reduced airway neutrophil
recruitment and MCP-1 production after low dose chal-
lenge with flagellated P. aeruginosa that was not observed
after challenge with an isotypic non-flagellated strain,
confirming a specific contribution of TLR5-dependent
pathways to the host inflammatory response [114].
In addition to TLR5-dependent recognition of flagellin,
P. aeruginosa LPS is detected by TLR4 and the P. aerugi-
nosa ExoS toxin is recognized by both TLR2 and TLR4
[11,115-117]. Loss of a single TLR does not confer sus-
ceptibility to P. aeruginosa infection while deletion of the
adaptor molecule MyD88 does confer hypersusceptibility,
increased lung bacterial load, and deficient neutrophil
recruitment [114,117-123]. Interestingly, MyD88 may
play an essential role only during the early phase of infec-
tion (4-8 hours) as inflammation and control of bacterial
load 48 hours after low dose infection occurred through
an undetermined MyD88-independent mechanism [119].
Both TLR2 and TLR4 signal through MyD88-dependent
and -independent pathways while TLR5 signals exclusively
through MyD88. Studies to determine the relative contri-
bution of TLR2, TLR4, and TLR5 have had conflicting
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domonal infection [123-125].
Staphylococcus aureus and Burkholderia cenocepacia
have been associated with early and advanced CF lung
disease, respectively [3]. B. cenocepacia provokes lung
epithelial damage and TNF-a secretion that leads to
severe pneumonia and sepsis in CF patients [126,127].
Excess inflammation and mortality in B. cenocepacia
infection occurred through flagellin-dependent activation
of TLR5 and MyD88 [128,129]. Another study showed
that, despite higher bacterial load, MyD88-deficient mice
had less inflammation and decreased mortality compared
to wild type mice infected with B. cenocepacia [130].
Chronic Obstructive Pulmonary Disease (COPD)
COPD includes disorders of the respiratory system that
are characterized by abnormal inflammation as well as
expiratory airflow limitation that is not fully reversible. In
humans, the main risk factor for COPD is smoking and
the disease prevalence rises with age [131]. Although the
pathogenesis of COPD is not well understood, various
aspects of lung innate immunity are impaired including
mucociliary clearance, AM function, and expression of
airway antimicrobial polypeptides [132]. As a result,
microbial pathogens frequently establish residence in the
lower respiratory tract and induce a vicious circle of
inflammation and infection that may contribute to pro-
gressive loss of lung function [133] (figure 1).
There is accumulating evidence that impaired innate
immunity is likely to contribute to the pathogenesis of
COPD [134]. An essential role for TLRs in the mainte-
nance of lung structural homeostasis under ambient
conditions was recently described [135]. In this study,
TLR4- and MyD88-deficient mice developed sponta-
neous age-related emphysema that was associated with
increased oxidant stress, cell death, and elastolytic activ-
ity. A detailed mechanistic analysis showed that TLR4
maintains a critical oxidant/antioxidant balance in the
lung by modulating the expression and activity of
NADPH oxidase 3 in structural cells. In light of this
finding, the free radicals and oxidant properties of
tobacco smoke have been hypothesized to subvert innate
immunity and cause lung cell necrosis and tissue
damage [136,137]. Indeed, mice with short-term cigar-
ette smoke exposure develop neutrophilic airway inflam-
mation that is dependent on TLR4, MyD88, and IL-1R1
signaling [138]. Consistent with these findings, C3H/HeJ
mice that have naturally defective TLR4 signaling
develop less chronic inflammation after 5 weeks of
cigarette smoke exposure [139]. Finally, long-term cigar-
ette smoke exposure induced strain-dependent emphy-
sema in mice in one study, although no specific
association to TLRs was described [140].
Several studies have evaluated TLR expression and
function in AMs from COPD patients, smokers, and
non-smokers. Using flow cytometry, one group showed
reduced TLR2 expression on AMs of COPD patients and
smokers compared to non-smokers following ex vivo
ligand stimulation. Upregulation of TLR2 mRNA and
protein expression was observed only in AMs from non-
smokers while no significant differences in TLR4 expres-
sion were demonstrated among these three groups [141].
Another report showed comparable AM expression of
TLR2, TLR4 or the co-receptors MD-2 or CD14 between
smokers and non-smokers [142], yet AM stimulation
with TLR2 or TLR4 ligands elicited lower mRNA and
protein expression of inflammatory cytokines (TNF-a,
IL-1b, IL-6) or chemokines (IL-8, RANTES) in smokers
that was associated with suppressed IRAK-1 and p38
phosphorylation and impaired NF-B activation [142].
From this data, the authors concluded that chronic LPS
exposure via cigarette smoking selectively reprograms
AMs and alters the inflammatory response to TLR2 and
TLR4 ligands [142]. Finally, another study showed
reduced TLR4 mRNA expression in nasal and tracheal
epithelial cells of smokers compared to healthy non-
smoking control subjects with no differences in TLR2
expression [143]. Relative to non-smokers, patients with
mild or moderate COPD showed increased expression of
TLR4 and HBD-2, a TLR4 inducible antimicrobial pep-
tide, while those with advanced COPD had a reduction in
TLR4 and HBD-2 expression [143]. Modulation of TLR4
expression by cigarette smoke extract was studied
in vitro and revealed a dose-dependent reduction in
TLR4 mRNA and protein expression as well as reduced
IL-8 secretion in the A549 alveolar epithelial cells [143].
Taken together, these findings point to dynamic regula-
tion of airway epithelial and AM TLRs in response to
diverse environmental stimuli. The differences in TLR
expression across studies could be related to variable LPS
content in tobacco smoke, bacterial colonization, or a
persistent inflammatory state. Increased TLR4 expression
in mild or moderate COPD may reflect a robust host
response, while the decreased TLR4 expression level in
association with severe COPD may reflect a loss of innate
immunity or an adaptive regulatory response.
The interaction of cigarette smoke and PRR activation
has been studied using mouse models. In one study, AMs
from mice that had been exposed to cigarette smoke for
eight weeks showed decreased cytokine (TNF-a,I L - 6 )
and chemokine (RANTES) production following in vitro
stimulation with double-stranded RNA, LPS, or NLR
agonists [144]. No alteration of TLR3 or TLR4 expression
was observed; however, there was decreased nuclear
translocation of the transcription factor NF-B. The
functional impairment of cytokine release was specific to
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[144]. A subsequent report found a synergistic interac-
tion of cigarette smoke and dsRNA or influenza virus
that leads to emphysema in mice through epithelial and
endothelial cell apoptosis as well as proteolysis [145].
This process was mediated by IL-12, IL-18, and IFN-g as
well as activation of antiviral response pathways includ-
ing the intracellular signaling adaptor protein IPS-1 and
the kinase PKR.
Defective innate immunity may predispose to acute
exacerbations of COPD that are characterized by acutely
worsening dyspnea, cough, sputum production, and
accelerated airflow obstruction [146]. Bacterial coloniza-
tion (Streptococcus pneumoniae, Haemophilus influen-
zae) or viral infection (Influenza A and B, Respiratory
Syncytial Virus) of the lower respiratory tract are pri-
mary causes of acute COPD exacerbations [146-152].
Virulent pneumococci express the toxin pneumolysin
that is able to physically interact with TLR4 [153-159].
Consistent with this finding, nasopharyngeal infection of
TLR4-deficient mice with S. pneumoniae causes
enhanced bacterial load, dissemination, and death com-
pared to wild type mice [158]. Interestingly, the role of
TLR4 seems to be specific to the nasopharynx as TLR4-
deficient mice exhibit only a modest impairment of host
defense following direct pneumococcal infection of the
lower respiratory tract [160]. TLR2 is also upregulated
following pneumococcal infection and enhances host
inflammatory responses [161,162]. Despite a modest
reduction of inflammatory mediator production, TLR2-
deficient mice can still clear high and low infectious
doses of S. pneumoniae, suggesting that another PRR
c o m p e n s a t e sf o rt h el o s so fT L R 2i nt h i sm o d e l
[160,163]. TLR9-deficient mice are slightly more suscep-
tible to pneumococcal infection compared to wild type
animals [164]. Conversely, abrogation of MyD88 signal-
ing leads to uncontrolled airway pneumococcal growth,
systemic bacterial dissemination and decreased immune
mediator (TNF-a and IL-6) expression [158,165,166].
The severe susceptibility phenotype of MyD88-deficient
mice compared to mice with a single deletion of TLR9
or combined deletion of TLR2 and TLR4 highlights the
crucial role of this downstream adaptor in host defense
against S. pneumoniae [158,160,163,164,167].
Non-typeable H. influenzae (NTHi) is another bacter-
ium that commonly colonizes the respiratory epithelium
and causes COPD exacerbations [168-171]. While NTHi
produces both TLR4 and TLR2 ligands, TLR4/MyD88 is
the dominant immune signaling pathway in vitro and
mediates bacterial clearance in vivo [172]. TLR4 signal-
ing in response to NTHi is entirely MyD88 dependent
as TRIF KO mice had an identical bacterial load com-
pared to wild type mice [172]. TLR3 may also play a
role in inflammatory mediator production in the
immune response to NTHi although its relative contri-
bution to bacterial clearance is not clear [173].
Asthma
Asthma is a potentially life-threatening chronic inflam-
matory airway disease that is characterized by episodic
bronchoconstriction, mucus hypersecretion, goblet cell
hyperplasia and tissue remodelling that may begin in
childhood. The underlying immune response in asthma
is targeted against environmental antigens including pol-
len or dust particles and is characterized by the presence
of antigen-specific Th2 cells in the lung that facilitate
production of antigen specific IgE [174,175]. Viral and
bacterial infections have been associated with induction
or protection against asthma, suggesting that innate
immunity plays an important role in disease pathogen-
esis [176]. On the basis of several epidemiologic, human,
and animal studies, the timing and extent of LPS expo-
sure, and presumably TLR4 activation, appears to deter-
mine whether a protective Th1 response or a permissive
Th2 response develops in the lung [177]. For example, it
was demonstrated that low dose administration of intra-
nasal LPS induces a Th2 biased immune response in the
lung whereas elsewhere in the body LPS is a strong
inducer of a Th1 immune response [178]. Nevertheless,
experimental treatment of mice with microbes [179] or
TLR agonists [180,181] inhibits allergic sensitization,
eosinophilic inflammation, and airways hyperresponsive-
ness. Recently, experimental intranasal infection of preg-
nant mice with Acinetobacter lwoffii F78 was shown to
confer protection against ovalbumin-induced asthma in
the progeny. Using knockout mice, the protective effect
was shown to be dependent on maternal TLR expres-
sion and suggests that microbial recognition during
pregnancy somehow primes the fetal lung environment
for a Th1 response later in life [182].
Lung resident cells that express TLR4 also play an
important role in the induction of allergen specific Th2
cells via recognition of house dust mite (a ubiquitous
indoor allergen) that leads to the production of thymic
stromal lymphopoietin, granulocyte-macrophage colony-
stimulating factor, IL-25 and IL-33. This cytokine milieu
can bias lung DCs towards a Th2 activating phenotype
that drives the polarization of naïve lymphocytes [183].
In addition, eosinophil derived neurotoxin can induce
TLR2-dependent DC maturation, leading to Th2 polari-
zation by secretion of high amounts of IL-6 and IL-10
[184] while basophils may also instruct T cells to
become Th2 cells [185].
TLRs have been shown via genetic association studies
as well as single and multiple gene knockout studies to
play a role in the development of allergic asthma. For
example TLR7 and TLR8 are associated with human
asthma [186] while ligands of TLR7 and TLR8 can
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induced asthma [187,188]. TLR10 single nucleotide
polymorphisms have also been associated with asthma
in two independent samples [189] although the ligand
for TLR10 has not been defined. Finally, in a multi-
centre asthma study, TLR4 and TLR9 were both asso-
ciated with wheezing and TLR4 was also associated with
allergen specific IgE secretion [190]. Based on this
observation, TLR9 ligands are currently in clinical trials
for the treatment or prevention of asthma [191].
Asthma can be further exacerbated by bacterial
respiratory tract infection including Mycoplasma pneu-
moniae or Chlamydophila pneumoniae [192]. In one
study, 50% of patients suffering from their first asth-
matic episode were infected with M. pneumoniae while
10% were serologically positive for acute C. pneumoniae
infection [193,194]. MyD88-deficient mice infected with
C. pneumoniae failed to upregulate cytokine and chemo-
kine expression, had delayed CD8
+ and CD4
+ T cell
recruitment, and could not clear the bacterium from the
lungs leading to severe chronic infection and signifi-
cantly increased mortality [195]. At a later stage of
infection, IL-1b,I F N - g and other inflammatory media-
t o r sm a yb eu p r e g u l a t e dv i aaM y D 8 8 - i n d e p e n d e n t
pathway but are not sufficient to prevent mortality from
C. pneumoniae [195]. TLR2 and TLR4-deficient mice
can recover from C. pneumoniae infection with no
impairment of bacterial clearance suggesting that other
PRRs are also involved in host defense or that TLR2/
TLR4 act in concert during C. pneumoniae infection
[195,196].
TLR2 is also upregulated in response to M. pneumo-
niae infection, leading to increased expression of airway
mucin [197,198]. Allergic inflammation along with the
induction of Th2 cytokines (IL-4, IL-13) leads to TLR2
inhibition during M. pneumoniae infection, thereby
decreasing the production of IL-6 and other Th1 proin-
flammatory mediators that are required for bacterial
clearance [199]. Antibiotic treatment of asthmatic
patients infected with M. pneumoniae improves their
pulmonary function and highlights the increasingly
important role that bacterial colonization and interac-
tions with the host innate immune response play in
asthma exacerbations and mortality [200,201].
Viral infection of the lower respiratory tract can also
contribute to asthma development and exacerbations.
Respiratory Syncytial Virus (RSV) is a particularly impor-
tant cause of acute bronchiolitis and wheezing in children
that may lead to the subsequent development of asthma
[202-206]. Wheezing after the acquisition of severe RSV
infection early in life has been associated with elevated
Th2 responses, eosinophilia, and IL-10 production
[207-211]. During RSV infection, the viral G protein
mediates attachment to lung epithelial cells and the F
protein leads to the fusion of the viral envelope with the
host cell plasma membrane [212]. In response to RSV
infection, TLRs are broadly upregulated in the human
tracheal epithelial cell line 9HTEo [213]. In mice, TLR4
has been shown to recognize the F protein and activate
NF-B during RSV infection [203,214]. Accordingly,
TLR4-deficient animals exhibit impaired NK cell function
and increased viral load [205,215]. Defective TLR4 signal-
ling has also been linked to increased pathology in a study
of pre-term infants [216]. An essential role for IL-12,
rather than TLR4, in susceptibility to RSV has also been
proposed [214]; however, significant differences in experi-
mental design limit the comparison of these apparently
discordant studies [217].
In human lung fibroblasts and epithelial cells, the for-
mation of dsRNA during RSV replication can activate
TLR3-mediated immune signaling, leading to the upre-
gulation of the chemokines RANTES and IP-10 [218].
TLR3-deficient mice have a predominantly Th2
response to RSV characterized by increased airway eosi-
nophilia, mucus hypersecretion and expression of IL-5
and IL-13 [219]. RIG-I-induced IFN-b expression during
RSV infection was recently shown to trigger TLR3 acti-
vation, suggesting that TLR3 mediates a secondary
immune signaling pathway [220]. Interestingly, while
TLR3 is involved in chemokine expression it has no role
in RSV viral clearance, which is primarily mediated by
the TLR2/TLR6 heterodimer [218,219].
In summary, the emerging picture of allergic asthma
suggests that the disease can be mediated or exacerbated
in genetically predisposed individuals by infection. In
some cases these infections may induce an inflammatory
state that protects against asthma, while in others the
infection may elicit an acute allergic response or bias
the host towards a subsequent Th2 response (figure 1).
Conclusion
Innate immunity is a principal mechanism for the main-
t e n a n c eo fl u n gt i s s u eh o m e o stasis despite continuous
exposure to environmental irritants and potentially
pathogenic microorganisms. In recent years tremendous
progress has been made with regard to how the TLRs
contribute to host defence and tissue repair. The
insights that have arisen from this work allow one to
postulate a few general principles with regard to lung
innate immunity. First, acute pulmonary diseases such
as ALI and bronchiolitis frequently develop into chronic
inflammatory states (fibroproliferative ARDS) or exhibit
a relapsing and remitting pattern (asthma). Second,
infectious diseases are principal causes of sustained lung
inflammation, as exemplified by severe influenza pneu-
monia that progresses to ARDS or severe RSV infection
that precedes the development of asthma. Third, defec-
tive innate immunity contributes to the development of
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ectly predisposing the host to infection, as observed in
CF patients with chronic P. aeruginosa infection or
acute exacerbations of COPD caused by S. pneumoniae.
Finally, tissue repair and remodelling are crucial to the
pathogenesis of lung inflammation as well as to host
defense, and based on current data it appears that TLR-
dependent mechanisms mediate the development of
both processes.
Despite extensive research, many questions remain
unanswered, including the relative contributions of TLR
and non-TLR PRRs to lung inflammation and protective
immunity, the precise nature of gene-environment inter-
actions in asthma pathogenesis, the molecular mechan-
isms that negatively regulate the innate immune
response during ALI, the failure of innate immunity to
sterilize the lower respiratory tract in CF, and the role
of innate immunity in tissue remodelling in asthma and
COPD. A deeper understanding of the basic biology of
TLRs will provide additional opportunities to elucidate
the links between innate immunity and the development
of acute and chronic inflammatory or infectious lung
diseases. Ultimately, it is our hope that such knowledge
will provide new strategies to limit the burden of
human suffering and death due to respiratory disease.
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